Filing Details

Accession Number:
0001144204-14-029240
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-05-09 21:03:47
Reporting Period:
2014-05-09
Filing Date:
2014-05-09
Accepted Time:
2014-05-09 21:03:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1270073 Intercept Pharmaceuticals Inc ICPT Pharmaceutical Preparations (2834) 223868459
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1559537 Paolo Fundaro C/O Intercept Pharmaceuticals, Inc.
450 W. 15Th Street, Suite 505
New York NY 10011
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-05-09 325 $0.00 1,980 No 4 M Direct
Common Stock Disposition 2014-05-09 325 $232.00 1,655 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2014-05-09 325 $0.00 325 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
324 No 4 M Direct
Footnotes
  1. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 5, 2013.
  2. Conversion of restricted stock units ("RSU") to shares of common stock on a one-for one-basis.
  3. On November 16, 2012, the reporting person was granted 2,596 RSUs. The RSUs reported as having been disposed and the corresponding shares reported as having been acquired, representing 12.5% of the shares underlying the RSUs, became vested on May 9, 2014, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remainder of the shares underlying the RSUs will vest on August 9, 2014, subject to the terms and conditions of the award and the 2012 Plan.